Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:PRPL NASDAQ:TDUP NASDAQ:TSHA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRPLPURPLE INNOVATION$0.86+1.6%$1.01$0.56▼$1.29$91.70M1.71395,486 shs259,523 shsTDUPThredUp$8.93+1.1%$10.11$0.50▼$12.28$1.09B1.711.49 million shs1.17 million shsTSHATaysha Gene Therapies$4.75-3.8%$3.63$1.05▼$5.51$1.35B0.9911.79 million shs2.28 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRPLPURPLE INNOVATION+1.28%-1.65%-17.07%-5.57%-9.76%TDUPThredUp-1.67%-3.07%-9.44%+14.82%+1,191.88%TSHATaysha Gene Therapies0.00%-2.76%+69.18%+86.42%+150.76%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRPLPURPLE INNOVATION$0.86+1.6%$1.01$0.56▼$1.29$91.70M1.71395,486 shs259,523 shsTDUPThredUp$8.93+1.1%$10.11$0.50▼$12.28$1.09B1.711.49 million shs1.17 million shsTSHATaysha Gene Therapies$4.75-3.8%$3.63$1.05▼$5.51$1.35B0.9911.79 million shs2.28 million shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRPLPURPLE INNOVATION+1.28%-1.65%-17.07%-5.57%-9.76%TDUPThredUp-1.67%-3.07%-9.44%+14.82%+1,191.88%TSHATaysha Gene Therapies0.00%-2.76%+69.18%+86.42%+150.76%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePRPLPURPLE INNOVATION 1.50Reduce$1.0016.39% UpsideTDUPThredUp 2.67Moderate Buy$13.0045.58% UpsideTSHATaysha Gene Therapies 2.91Moderate Buy$9.67103.51% UpsideCurrent Analyst Ratings BreakdownLatest TSHA, TDUP, and PRPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/21/2025TSHATaysha Gene TherapiesRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$13.0010/17/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.0010/17/2025TSHATaysha Gene TherapiesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.0010/8/2025PRPLPURPLE INNOVATIONWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025TDUPThredUpWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025TSHATaysha Gene TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/2/2025TSHATaysha Gene TherapiesRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $12.0010/2/2025TSHATaysha Gene TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $10.009/27/2025PRPLPURPLE INNOVATIONWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TDUPThredUpWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TSHATaysha Gene TherapiesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPRPLPURPLE INNOVATION$487.88M0.19N/AN/A$0.19 per share4.52TDUPThredUp$260.03M4.23N/AN/A$0.48 per share18.60TSHATaysha Gene Therapies$8.33M155.56N/AN/A$0.35 per share13.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePRPLPURPLE INNOVATION-$97.90M-$0.78N/AN/AN/A-18.43%-472.12%-13.20%11/3/2025 (Estimated)TDUPThredUp-$76.99M-$0.490.00N/AN/A-19.66%-71.49%-23.61%11/3/2025 (Estimated)TSHATaysha Gene Therapies-$89.30M-$0.340.00N/AN/A-1,144.97%-78.44%-44.82%11/12/2025 (Estimated)Latest TSHA, TDUP, and PRPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025TSHATaysha Gene Therapies-$0.09N/AN/AN/A$1.51 millionN/A11/3/2025Q3 2025PRPLPURPLE INNOVATION-$0.09N/AN/AN/A$123.21 millionN/A11/3/2025Q3 2025TDUPThredUp-$0.04N/AN/AN/A$77.34 millionN/A8/12/2025Q2 2025TSHATaysha Gene Therapies-$0.07-$0.09-$0.02-$0.09$1.61 million$1.99 million7/29/2025Q2 2025PRPLPURPLE INNOVATION-$0.12-$0.11+$0.01-$0.16$103.69 million$105.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPRPLPURPLE INNOVATIONN/AN/AN/AN/AN/ATDUPThredUpN/AN/AN/AN/AN/ATSHATaysha Gene TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPRPLPURPLE INNOVATION54.691.490.77TDUPThredUp0.270.960.96TSHATaysha Gene Therapies0.1712.4812.48Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPRPLPURPLE INNOVATION88.41%TDUPThredUp89.08%TSHATaysha Gene Therapies77.70%Insider OwnershipCompanyInsider OwnershipPRPLPURPLE INNOVATION53.90%TDUPThredUp27.00%TSHATaysha Gene Therapies3.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePRPLPURPLE INNOVATION1,200108.41 million49.98 millionOptionableTDUPThredUp1,630123.16 million89.91 millionOptionableTSHATaysha Gene Therapies180272.80 million262.48 millionOptionableTSHA, TDUP, and PRPL HeadlinesRecent News About These CompaniesRaymond James Initiates Coverage of Taysha Gene Therapies (TSHA) with Strong Buy RecommendationOctober 22 at 4:19 AM | msn.comTaysha Gene Therapies (NASDAQ:TSHA) Trading Up 9.1% - Time to Buy?October 22 at 2:59 AM | marketbeat.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesOctober 22 at 2:49 AM | americanbankingnews.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Average Rating of "Moderate Buy" by AnalystsOctober 22 at 2:47 AM | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up - Time to Buy?October 21 at 11:59 AM | marketbeat.comRaymond James Financial Begins Coverage on Taysha Gene Therapies (NASDAQ:TSHA)October 21 at 8:09 AM | marketbeat.comTaysha Gene Therapies initiated with a Strong Buy at Raymond JamesOctober 20, 2025 | msn.comTaysha Gene Therapies' (TSHA) "Buy" Rating Reiterated at Needham & Company LLCOctober 20, 2025 | americanbankingnews.comTaysha Gene Therapies' (TSHA) Buy Rating Reiterated at Chardan CapitalOctober 20, 2025 | americanbankingnews.comTaysha Gene Therapies (NASDAQ:TSHA) Shares Down 11.9% - Here's What HappenedOctober 18, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Needham & Company LLCOctober 18, 2025 | marketbeat.comTaysha Gene Therapies (NASDAQ:TSHA) Earns "Buy" Rating from Chardan CapitalOctober 18, 2025 | marketbeat.comHow Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment StoryOctober 17, 2025 | finance.yahoo.comTaysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeOctober 17, 2025 | finanznachrichten.deAstellas walks away from gene therapy pact with Taysha before pivotal trial launchOctober 17, 2025 | fiercebiotech.comFNeedham Reiterates Taysha Gene Therapies (TSHA) Buy RecommendationOctober 17, 2025 | msn.comTaysha Gene Therapies Regains Full Rights to Rett Syndrome ProgramOctober 16, 2025 | marketwatch.comTaysha Gene Therapies regains full rights to TSHA-102 programOctober 16, 2025 | msn.comTaysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett SyndromeOctober 16, 2025 | globenewswire.comTaysha Gene Therapies (NASDAQ:TSHA) Hits New 52-Week High - Should You Buy?October 15, 2025 | marketbeat.comTruist Financial Remains a Buy on Taysha Gene Therapies (TSHA)October 12, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTSHA, TDUP, and PRPL Company DescriptionsPURPLE INNOVATION NASDAQ:PRPL$0.86 +0.01 (+1.57%) Closing price 04:00 PM EasternExtended Trading$0.86 0.00 (-0.26%) As of 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Innovation, Inc. designs and manufactures sleep and other products in the United States and internationally. The company offers mattresses, pillows, cushions, bases, sheets, platforms, adjustable bases, mattress protectors, foundations, blankets, duvets, duvet covers, seat cushions, and pet beds under the Purple brand. It markets and sells its products through its e-commerce online channels, retail brick-and-mortar wholesale partners, third-party online retailers, and Purple showrooms, as well as through its website, Purple.com. The company was founded in 2010 and is headquartered in Lehi, Utah.ThredUp NASDAQ:TDUP$8.93 +0.10 (+1.13%) Closing price 04:00 PM EasternExtended Trading$8.92 -0.01 (-0.11%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ThredUp Inc., together with its subsidiaries, operates an online resale platform in the United States and internationally. Its platform enables consumers to buy and sell primarily secondhand apparel, shoes, and accessories. ThredUp Inc. was incorporated in 2009 and is headquartered in Oakland, California.Taysha Gene Therapies NASDAQ:TSHA$4.75 -0.19 (-3.85%) Closing price 04:00 PM EasternExtended Trading$4.76 +0.00 (+0.11%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
